“I believed in the power of PhysioPD when I first saw it twenty-five years ago, I’ve had a passion for it ever since, and now we have enough experience that I know it works.”
—Ron Beaver, PhD, Founder

About Rosa & Co

Rosa was founded in 2002 and remains an employee-owned, science-focused, and client-friendly firm. Today, Rosa is the worldwide commercial leader in PhysioPD-style Research, with comprehensive basic biology and therapeutic experience, industry-leading modeling expertise, and repeat research engagements with a majority of the Top 20 pharmaceutical companies.

Rosa's ForecastMD Platforms, which offers a credible methodology for determining expected physician uptake for healthcare products, was started by Bill Brastow, Ph.D., in 2005. Our models have helped shape first-in-class markets including novel therapy combinations for HIV and molecular diagnostic tests for Oncology.

Rosa’s staff bring more than a century of aggregate experience in applying modeling to the inherent challenges faced by drug developers and have authored hundreds of scientific posters, conference presentations, relevant patents, and peer-reviewed publications.

Recent Highlights

Rosa & Co. announces the preprint publication of an article on modeling opiod overdose reversal

Rosa & Co. announced today the preprint publication of an article titled, “Brief Report: Higher Fentanyl Exposures Require Higher Doses of Naloxone for Successful Reversals in a Quantitative Systems Pharmacology Model,” which was published on Res... Read More

Rosa & Co. announces the contributions of Rosa scientists to the publication of an article on modeling PI3K-inhibitor-induced colitis

Rosa & Co. announced today the contributions of Drs. Christina Friedrich, Vincent Hurez, and Maria-Luisa Ruiz to the article titled, “Quantitative systems pharmacology model-based investigation of adverse gastrointestinal events associated with p... Read More

Rosa & Co. announces contributions of Dr. Christina Friedrich to the publication of an article on FDA-Industry Scientific Exchange

Rosa & Co. announced today the contributions of Dr. Christina Friedrich, Chief Engineer at Rosa, to the article titled, “FDA-Industry Scientific Exchange on assessing quantitative systems pharmacology models in clinical drug development: a meetin... Read More

Webinar showcases how Rosa Market Modeling is used to optimize competitive positioning

Today, Rosa & Co. announced that Dr. Bill Brastow, Chief Technology Officer at Rosa Market Modeling, will present a webinar entitled “Driving Market Share for Healthcare Products by Integrating Market Modeling” on Wednesday, March 18. Hosted in p... Read More

The Rosa & Co. Executive Team